<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04201067</url>
  </required_header>
  <id_info>
    <org_study_id>16-004682</org_study_id>
    <secondary_id>U54NS115198-01</secondary_id>
    <nct_id>NCT04201067</nct_id>
  </id_info>
  <brief_title>Large-Scale Metabolomic Profiling for the Diagnosis of Inborn Errors of Metabolism</brief_title>
  <official_title>Large-Scale Metabolomic Profiling for the Diagnosis of Inborn Errors of Metabolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Researchers are trying to determine the efficacy of a global metabolomic approach in testing
      for and diagnosing inborn errors of metabolism as opposed to traditional testing methods.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Residual samples will be tested for a variety of biomarkers that may lead to better
      understanding of these disorders and help develop treatment options.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 8, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Quantify N-linked glycan intermediates in plasma and urine</measure>
    <time_frame>length of study, up to 5 years</time_frame>
    <description>Measure N-linked glycan intermediates in plasma and urine from PMM2-CDG patients.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Develop quantitative biomarkers for PGM1-CDG patients to monitor the efficacy of galactose therapy.</measure>
    <time_frame>length of study, up to 5 years</time_frame>
    <description>Measure the 41 plasma N-glycan levels in 9 PGM1-CDG patients before and after galactose therapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Develop quantitative biomarkers for SLC35A2-CDG patients and monitor galactose therapy efficacy.</measure>
    <time_frame>length of study, up to 5 years</time_frame>
    <description>Measure levels of plasma N-glycans from 10 SLC35A2-CDG patients before and after galactose therapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Validate biomarker to diagnose and follow NGLY1 deficiency and monitor N-acetylglucosamine (GlcNAc) therapy response.</measure>
    <time_frame>length of study, up to 5 years</time_frame>
    <description>Measure the level of Sia-Gal-GlcNAc-Asn biomarker excretion during GlCNAc therapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Validate novel diagnostic biomarkers for ALG13-CDG</measure>
    <time_frame>length of study, up to 5 years</time_frame>
    <description>Measure GlcNAc-Î²-Asn on glycoproteins in the cells from the already available fibroblast of 9 ALG13 patients.</description>
  </primary_outcome>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Congenital Disorders of Glycosylation</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Stool, urine, DBS, fibroblasts, and blood can be retained for biomarker testing. DNA may be a
      part of this testing in the future.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        These individuals will likely have a congenital disorder of glycosylation or other
        metabolic disease.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All individuals with specimens in Biochemical Genetics Laboratory and from patients
             collected under another IRB who have agreed to share samples/data

        Exclusion Criteria:

          -  None
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eva Morava-Kozicz, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 8, 2019</study_first_submitted>
  <study_first_submitted_qc>December 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2019</study_first_posted>
  <last_update_submitted>December 16, 2019</last_update_submitted>
  <last_update_submitted_qc>December 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Eva Morava-Kozicz</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolism, Inborn Errors</mesh_term>
    <mesh_term>Congenital Disorders of Glycosylation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Information and samples can be shared at PI's discretion.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>length of study</ipd_time_frame>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 7, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/67/NCT04201067/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

